p53 gene mutations in pituitary adenomas: Rare events

A. Levy, L. Hall, William Andrew Yeudall, S. L. Lightman

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Objective. Occult pituitary adenomas are said to occur in up to 20% of random autopsy examinations, yet the only oncogene known to be associated with pituitary adenomas, gsp, is found in only 40% of somatotrophinomas, a subtype that accounts for a minority of pituitary tumours. Mutations of the p53 tumour suppressor gene are thought to be involved in the pathogenesis of as many as 50% of all human cancers, including tumours of the central nervous system. The objective of this study was to determine whether p53 gene mutations are associated with pituitary adenomas. Design and patients. Fragments of pituitary adenoma tissue from 29 patients undergoing routine hypophysectomy for pituitary tumour were coated in cryostat embedding medium and frozen at -80°C within 24 hours of resection. They consisted of 9 somatotroph, 4 corticotroph, 1 mammotroph and 15 endocrinologically inactive adenomas, all of the non-invasive clinical phenotype. Sequential frozen sections were subjected to in situ hybridization analysis for anterior pituitary hormone transcripts and examined histologically to ensure that the frozen sections used to generate DNA templates for polymerase chain reaction amplification were not contaminated with non-tumour tissue. Measurements. p53 exons 7 and 8, within which 98% of substitution mutations are thought to occur, and exons 4-6 in tumours immunopositive for p53, were amplified by polymerase chain reaction and ligated into the vector pCR2. DNA from small-scale plasmid preparations of pCR2 containing cloned p53 exons from human pituitary adenomas was sequenced using an automated fluorescence-based system (DuPont Genesis 2000) and compared with wild-type sequence. Apparent mutations were confirmed or refuted by sequencing a further 2-4 clones isolated from the same template. Results. Although immunocytochemical staining patterns for wild-type p53 varied markedly between different tumours, no mutations were identified in any of the exonic sequences examined. Conclusions. p53 mutations, at least within the high mutation domains of p53, occur infrequently in human pituitary adenomas. Increased steady-state levels of p53 protein identified immunocytochemically may be a consequence of binding to other cellular proteins in these tumours.

Original languageEnglish (US)
Pages (from-to)809-814
Number of pages6
JournalClinical Endocrinology
Volume41
Issue number6
StatePublished - Dec 1 1994
Externally publishedYes

Fingerprint

p53 Genes
Pituitary Neoplasms
Mutation
Exons
Frozen Sections
Neoplasms
Corticotrophs
Somatotrophs
Anterior Pituitary Hormones
Central Nervous System Neoplasms
Polymerase Chain Reaction
Hypophysectomy
DNA-Directed DNA Polymerase
Tumor Suppressor Genes
Oncogenes
Adenoma
In Situ Hybridization
Autopsy
Proteins
Plasmids

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Levy, A., Hall, L., Yeudall, W. A., & Lightman, S. L. (1994). p53 gene mutations in pituitary adenomas: Rare events. Clinical Endocrinology, 41(6), 809-814.

p53 gene mutations in pituitary adenomas : Rare events. / Levy, A.; Hall, L.; Yeudall, William Andrew; Lightman, S. L.

In: Clinical Endocrinology, Vol. 41, No. 6, 01.12.1994, p. 809-814.

Research output: Contribution to journalArticle

Levy, A, Hall, L, Yeudall, WA & Lightman, SL 1994, 'p53 gene mutations in pituitary adenomas: Rare events', Clinical Endocrinology, vol. 41, no. 6, pp. 809-814.
Levy A, Hall L, Yeudall WA, Lightman SL. p53 gene mutations in pituitary adenomas: Rare events. Clinical Endocrinology. 1994 Dec 1;41(6):809-814.
Levy, A. ; Hall, L. ; Yeudall, William Andrew ; Lightman, S. L. / p53 gene mutations in pituitary adenomas : Rare events. In: Clinical Endocrinology. 1994 ; Vol. 41, No. 6. pp. 809-814.
@article{b76a2a1a07324fee8025dd0e83ec3c34,
title = "p53 gene mutations in pituitary adenomas: Rare events",
abstract = "Objective. Occult pituitary adenomas are said to occur in up to 20{\%} of random autopsy examinations, yet the only oncogene known to be associated with pituitary adenomas, gsp, is found in only 40{\%} of somatotrophinomas, a subtype that accounts for a minority of pituitary tumours. Mutations of the p53 tumour suppressor gene are thought to be involved in the pathogenesis of as many as 50{\%} of all human cancers, including tumours of the central nervous system. The objective of this study was to determine whether p53 gene mutations are associated with pituitary adenomas. Design and patients. Fragments of pituitary adenoma tissue from 29 patients undergoing routine hypophysectomy for pituitary tumour were coated in cryostat embedding medium and frozen at -80°C within 24 hours of resection. They consisted of 9 somatotroph, 4 corticotroph, 1 mammotroph and 15 endocrinologically inactive adenomas, all of the non-invasive clinical phenotype. Sequential frozen sections were subjected to in situ hybridization analysis for anterior pituitary hormone transcripts and examined histologically to ensure that the frozen sections used to generate DNA templates for polymerase chain reaction amplification were not contaminated with non-tumour tissue. Measurements. p53 exons 7 and 8, within which 98{\%} of substitution mutations are thought to occur, and exons 4-6 in tumours immunopositive for p53, were amplified by polymerase chain reaction and ligated into the vector pCR2. DNA from small-scale plasmid preparations of pCR2 containing cloned p53 exons from human pituitary adenomas was sequenced using an automated fluorescence-based system (DuPont Genesis 2000) and compared with wild-type sequence. Apparent mutations were confirmed or refuted by sequencing a further 2-4 clones isolated from the same template. Results. Although immunocytochemical staining patterns for wild-type p53 varied markedly between different tumours, no mutations were identified in any of the exonic sequences examined. Conclusions. p53 mutations, at least within the high mutation domains of p53, occur infrequently in human pituitary adenomas. Increased steady-state levels of p53 protein identified immunocytochemically may be a consequence of binding to other cellular proteins in these tumours.",
author = "A. Levy and L. Hall and Yeudall, {William Andrew} and Lightman, {S. L.}",
year = "1994",
month = "12",
day = "1",
language = "English (US)",
volume = "41",
pages = "809--814",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - p53 gene mutations in pituitary adenomas

T2 - Rare events

AU - Levy, A.

AU - Hall, L.

AU - Yeudall, William Andrew

AU - Lightman, S. L.

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Objective. Occult pituitary adenomas are said to occur in up to 20% of random autopsy examinations, yet the only oncogene known to be associated with pituitary adenomas, gsp, is found in only 40% of somatotrophinomas, a subtype that accounts for a minority of pituitary tumours. Mutations of the p53 tumour suppressor gene are thought to be involved in the pathogenesis of as many as 50% of all human cancers, including tumours of the central nervous system. The objective of this study was to determine whether p53 gene mutations are associated with pituitary adenomas. Design and patients. Fragments of pituitary adenoma tissue from 29 patients undergoing routine hypophysectomy for pituitary tumour were coated in cryostat embedding medium and frozen at -80°C within 24 hours of resection. They consisted of 9 somatotroph, 4 corticotroph, 1 mammotroph and 15 endocrinologically inactive adenomas, all of the non-invasive clinical phenotype. Sequential frozen sections were subjected to in situ hybridization analysis for anterior pituitary hormone transcripts and examined histologically to ensure that the frozen sections used to generate DNA templates for polymerase chain reaction amplification were not contaminated with non-tumour tissue. Measurements. p53 exons 7 and 8, within which 98% of substitution mutations are thought to occur, and exons 4-6 in tumours immunopositive for p53, were amplified by polymerase chain reaction and ligated into the vector pCR2. DNA from small-scale plasmid preparations of pCR2 containing cloned p53 exons from human pituitary adenomas was sequenced using an automated fluorescence-based system (DuPont Genesis 2000) and compared with wild-type sequence. Apparent mutations were confirmed or refuted by sequencing a further 2-4 clones isolated from the same template. Results. Although immunocytochemical staining patterns for wild-type p53 varied markedly between different tumours, no mutations were identified in any of the exonic sequences examined. Conclusions. p53 mutations, at least within the high mutation domains of p53, occur infrequently in human pituitary adenomas. Increased steady-state levels of p53 protein identified immunocytochemically may be a consequence of binding to other cellular proteins in these tumours.

AB - Objective. Occult pituitary adenomas are said to occur in up to 20% of random autopsy examinations, yet the only oncogene known to be associated with pituitary adenomas, gsp, is found in only 40% of somatotrophinomas, a subtype that accounts for a minority of pituitary tumours. Mutations of the p53 tumour suppressor gene are thought to be involved in the pathogenesis of as many as 50% of all human cancers, including tumours of the central nervous system. The objective of this study was to determine whether p53 gene mutations are associated with pituitary adenomas. Design and patients. Fragments of pituitary adenoma tissue from 29 patients undergoing routine hypophysectomy for pituitary tumour were coated in cryostat embedding medium and frozen at -80°C within 24 hours of resection. They consisted of 9 somatotroph, 4 corticotroph, 1 mammotroph and 15 endocrinologically inactive adenomas, all of the non-invasive clinical phenotype. Sequential frozen sections were subjected to in situ hybridization analysis for anterior pituitary hormone transcripts and examined histologically to ensure that the frozen sections used to generate DNA templates for polymerase chain reaction amplification were not contaminated with non-tumour tissue. Measurements. p53 exons 7 and 8, within which 98% of substitution mutations are thought to occur, and exons 4-6 in tumours immunopositive for p53, were amplified by polymerase chain reaction and ligated into the vector pCR2. DNA from small-scale plasmid preparations of pCR2 containing cloned p53 exons from human pituitary adenomas was sequenced using an automated fluorescence-based system (DuPont Genesis 2000) and compared with wild-type sequence. Apparent mutations were confirmed or refuted by sequencing a further 2-4 clones isolated from the same template. Results. Although immunocytochemical staining patterns for wild-type p53 varied markedly between different tumours, no mutations were identified in any of the exonic sequences examined. Conclusions. p53 mutations, at least within the high mutation domains of p53, occur infrequently in human pituitary adenomas. Increased steady-state levels of p53 protein identified immunocytochemically may be a consequence of binding to other cellular proteins in these tumours.

UR - http://www.scopus.com/inward/record.url?scp=0028592564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028592564&partnerID=8YFLogxK

M3 - Article

C2 - 7889618

AN - SCOPUS:0028592564

VL - 41

SP - 809

EP - 814

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 6

ER -